Binnopharm to acquire two antibacterial brands from Dr Reddys

The company will acquire Dr Reddy's Laboratories' anti-bacterial medicines under the Ciprolet and Levolet brands in Russia, Uzbekistan and Belarus. The product portfolio includes various dosage forms such as tablets, solution for infusions and eye drops. Sistema Group company Binnopharm Group will acquire Dr Reddy's Laboratories' antibacterial medicines under the Ciprolet and Levolet brands in Russia, Uzbekistan and Belarus, the companies said in a joint statement on Monday. The Binnopharm Group, which is one of the leading pharmaceutical production companies in Russia, has inked a deal with Dr Reddy's in this regard. The product portfolio includes various dosage forms such as tablets, solution for infusions and eye drops.The acquisition of Ciprolet and Levolet is an important step to enhance our position in the antibiotics market, one of the key market segments for Binnopharm Group. These strong brands have already had the trust of millions of consumers - according to independent analyst estimation they are leaders in their market segments," Binnopharm Group CEO Rustem Muratov said in a statement. The products will be a valuable complement to the company's portfolio of antibacterial products, he added. "We are also acquiring rights to these products in Belarus and Uzbekistan in line with our strategic goal to strengthen presence in the international markets," Muratov noted. Dr Reddy's CEO - Branded Markets (India & Emerging Markets) M V Ramana said the drug firm's Russia and CIS markets continue to be strong performers. "This deal is a step towards divesting brands in non-core areas in order to consolidate and strengthen our play further in our key focus therapy areas of gastro-enterology, pain management, cold and flu, allergy, oncology, neurology, paediatrics and women's health," he said. During the transition period, Dr Reddy's will continue to supply the product to Binnopharm Group to ensure availability in the market

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!